Introduction {#sec1-1}
============

Diabetes mellitus (DM) is defined as a disturbance of intermediary metabolism, manifesting as a chronic sustained hyperglycemia primarily due to either an absolute or relative lack of insulin.\[[@ref1]\] Type II DM appears to be prevalent at "epidemic" levels in many places. In areas of Australia, 7% of the people over 25 years old have DM (mostly type II).\[[@ref2]\] India has already become the " Diabetes Capital" of the world, with over 3 crore affected patients, which is a tip of iceberg.\[[@ref3]\] It has turned out to be the biggest "silent killer" today in the world. Type I DM is nearer to *Dhatuapakarshanajanya Madhumeha* while the type II DM resembles *Avaranajanya Madhumeha. Acharya Sushruta* has mentioned that in *Madhumeha*, the vitiated *doshas* remain in the lower part of the body owing to the inefficiency of various Dhamanis, i.e. vessels.\[[@ref4]\] Therefore, in the present study, Virechana process has been selected prior to the administration of *Shamana* drug. *Nyagrodhadi churna* is mentioned in Chakradatta and is modified into ghanvati for easy administration.\[[@ref5]\] In this formulation, many drugs like *Vata, Udumber, Aswatha, Bijaka, Amra, Jambu, Arjuna, Dhava, Paribhadra, Meshashringi, Chitrak, Karanja, Triphala, Kutaja, Bhallataka*, etc. are *Madhumehahara*, indicated by Acharyas. *Amalaki* is an immunomodulator along with anti-hyperglycemic effect, and thus may be used in autoimmune DM. Similar effects are found in *Bhallataka, Haritaki, Mulethi, Madhuka, Dhava*, etc. The drugs like *Bijaka, Arjuna, Chitraka, Patola, Meshashringi, Amalaki, Haritaki*, etc. have a hypolipidemic action.

Aims and Objectives {#sec1-2}
===================

To study the etiopathogenesis of *Madhumeha* (DM).To evaluate the role of *Shamana* drug in the management of *Madhumeha*.To compare the effect of *Shodhana* and *Shamana Chikitsa* in the management of *Madhumeha*.

Materials and Methods {#sec1-3}
=====================

The present study included patients, various investigations, selected drug and diet.

Criteria for selection {#sec2-1}
----------------------

Patients having classical signs and symptoms of *Madhumeha* (DM) were selected randomly from the OPD or admitted in the IPD of *Kayachikitsa* and *Panchakarma* department, I.P.G.T. and R.A., Jamnagar hospital, irrespective of age, sex, caste, religion, occupation, etc. The known cases of DM patients were also selected for the study after confirming by various investigations.

Exclusion criteria {#sec2-2}
------------------

Patients of Insulin dependant diabetes mellitus (IDDM).Patients complicated with any cardiac problem.Diabetes due to endocrinopathies, e.g. phaeochromocytoma, acromegaly, Cushing\'s syndrome, hyperthyroidism, etc.Drug- or chemical-induced DM, e.g. glucocorticoids, thyroid hormone, thiazides, phenytoin, etc.Certain genetic syndromes sometimes associated with DM, e.g. Down\'s syndrome, Klinefelter\'s syndrome, Turner\'s syndrome, etc.Patients suffering from any severe systemic disease.

Investigations {#sec2-3}
--------------

Routine hematological examinations like Hb% (Haemoglobin), TLC (Total Leucocyte count), DLC (Differential Leucocyte count), ESR (Erythrocyte sedimentation Rate), and PCV (Packed Cell Volume) were performed to rule out any other pathological condition.

Biochemical examinations {#sec2-4}
------------------------

Blood sugar: Fasting and post-prandial.Lipid profile: Serum cholesterol, serum triglyceride, serum S. HDL (High density lipoprotein), LDL (Low density lipoprotein), VLDL (Very low density lipoprotein)Serum insulin: Fasting.Blood urea and serum creatinine: To assess the functional status of the kidney.

Urine: Routine and microscopic examination.

Stool: Routine and microscopic examination.

These investigations were carried out in all the patients before treatment and after completion of treatment.

Plan of study {#sec2-5}
-------------

The selected patients were categorized randomly into the following two groups:

1)*Nyagrodhadi Ghanavati (Shamana* Yoga) group: Twenty-one patients of *Madhumeha* were included in this group and were given *Nyagrodhadi Ghanavati* at a dose of two vati thrice daily with lukewarm water before taking meals for a duration of 30 days.2)*Virechana* and *Nyagrodhadi Ghanavati* (combined therapy) group: Twenty-one patients of *Madhumeha* were registered in this group. Before selecting the patients for *Virechana*, they were examined for their general condition as well as to determine whether there was any disorder in which *Virechana* therapy was contraindicated. In this group, firstly, *Virechana* was given and, after that, *Nyagrodhadi Ghanavati* was given with the same schedule as in the *Shamana* therapy group.

Criteria for assessment {#sec2-6}
-----------------------

After completion of the treatment, the results were assessed by adopting the following criteria:

Improvement in signs and symptoms of disease on the basis of the symptoms score.Fasting blood Sugar (F.B.S.) and Post prandial blood sugar (P.P.B.S.) levels.Serum cholesterol.Urine sugar.

Assessment of the overall effect of therapy {#sec2-7}
-------------------------------------------
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Observations and Discussion {#sec1-4}
===========================

The [Table 1](#T1){ref-type="table"} shows total of 42 patients of Madhumeha were selected in this study.

###### 

Status of patients
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General observations {#sec2-8}
--------------------

A majority of the patients in this study, i.e. 35.71%, belonged to the age group of 51--60 years. These findings were concordant with the recent statistical data, which shows that the onset of Type II DM after the 40s is most common.

A majority of the patients, i.e. 85.71%, were living in urban areas and 14.28% of the patients were from rural areas. This data is concordant with the recent W.H.O. Annual Report (2000) that the prevalence of DM is greater in the urban than in the rural areas. After the housewives, i.e. 35.71%, the businessmen (30.95%) were maximum in number. The figure shows that disease occurs in those classes who usually lead a sedentary lifestyle and eat more than what is required. 59.52% of the patients confirmed a family history of *Madhumeha*, which shows that genetic predisposition is more important in type II DM.

A majority of the patients, i.e. 40.47%, were suffering from the disease for \>10 years and were followed by 23.80% patients with chronicity of 1-5 years. The maximum number of patients, i.e. 38.09%, were of Vataj-*Kaphaja* Prakriti. The majority of the patients, i.e. 76.19%, had *Madhyama Sara*, followed by *Madhyama Samhanana* (90.47%) and Madhyama Satva (85.71%). The maximum number of patients, i.e. 57.14%, were found to have *Vishamagni*, followed by 28.57% having Samagni \[[Figure 1](#F1){ref-type="fig"}\]. These findings indicate the dominancy of *Vata Dosha* in the *Samprapti* of *Madhumeha*. It was found that maximum patients i.e 58.45% were taking katu-tikta and kashaya rasa while 54.76% were taking Dadhi which were the predominant nidanas \[[Figure 2](#F2){ref-type="fig"}\]. Among the Chief complaints found, maximum patients reported Karapadataladaha, kshudhadhikya and trishnaadhikya ( 69.04%) each \[[Figure 3](#F3){ref-type="fig"}\].
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Effect of Therapies {#sec2-9}
-------------------

Group I-*Nyagrodhadi Ghanvati (Shamana* group)

Effect of *Nyagrodhadi Ghanavati* on chief complaints {#sec2-10}
-----------------------------------------------------

The [Table 2](#T2){ref-type="table"} reveals that the *Nyagrodhadi Ghanavati* group provided a statistically highly significant (*P* \< 0.001) relief in *Prabhuta Mutrata* by 78.94%, *Avila Mutrata* by 71.42%, *Kshudhadhikya* by 73.17% and *Trishnadhikya* by 77.14%, whereas the relief obtained in *Kara-pada-tala-daha* was 83.33%, which was statistically significant (*P* \< 0.001). On associated signs and symptoms, it provided statistically highly significant relief (P\<0.001) in *Alasya* (67.21%), *Daurbalya* (84.61%), *Atisweda* (79.31%), and *Kara-pada-supti* (82.97%) \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of *Nyagrodhadi Ghanavati* on chief complaints
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###### 

Effect of *Nyagrodhadi Ghanavati* on associated symptoms
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The therapy showed 1.67% relief in fasting blood sugar, which was statistically insignificant (*P* \< 0.10), whereas it showed no relief in the values of post-prandial blood sugar \[[Table 4](#T4){ref-type="table"}\]. In shamana group, 44.44% patients were found markedly improved and 55.55% patients were moderately improved \[[Table 5](#T5){ref-type="table"}\].

###### 

Effect of *Nyogrodhadi Ghanavati* on biochemical values
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###### 

Total effect of *Nyagrodhadi Ghanavati* on 18 patients of *Madhumeha*
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The combined therapy provided statistically highly significant relief (*P* \< 0.001) in *Prabhuta Mutrata* (90.24%), *Trishnadhikya* (87.17%) and *Kshudhadhikya* (83.33%), *Avila Mutrata* (88.88%) and *Kara-pada-tala Daha* (88.09%) \[[Table 6](#T6){ref-type="table"}\]. The therapy provided statistically highly significant (*P*\<0.001) relief in *Alasya* (79.62%), *Daurbalya* (86.66%), *Ati-sweda* (73.58%), *Kara-pada-supti* (91.30%) \[[Table 7](#T7){ref-type="table"}\].

###### 

Effect of Combined therapy on chief complaints
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###### 

Effect of combined therapy on associated symptoms
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The therapy provided statistically non-significant relief (*P* \< 0.10) in the fasting blood sugar level (10.53%) and post-prandial blood sugar (6.43%) level \[[Table 8](#T8){ref-type="table"}\].

###### 

Effect of combined therapy on biochemical values
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In this group, 68.75% of the patients were found to be markedly improved and 31.25% of the patients were found to be moderately improved. No patient was assessed as controlled and mild improved and unchanged in this group \[[Table 9](#T9){ref-type="table"}\].

###### 

Total effect of combined therapy on 16 patients of *Madhumeha*
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Acharya Charaka has classified *Prameha* into two types, i.e. *Sthula Pramehi* and *Krisha Pramehi*.\[[@ref6]\] He has advocated *Samshodhana* in *Sthulapramehi*, whose *doshas* have aggravated, and in patients having sufficient *bala* (strength). Hence, here, *Virechana Karma* is selected for such types of patients. Also, as said by Acharya Vagbhatta, there are no chances of vititation of doshas after doing *Samshodhana*.\[[@ref7]\]

Probable mode of action {#sec2-11}
-----------------------

### Nyogrodhadi Ghana Vati {#sec3-1}

The ingredients of *Nyagrodhadi Ghana Vati* are having *Tikta Rasa* (32.14%), *Kashaya Rasa* (75%), *Katu Rasa* (35.14%), *Madhura Rasa* (42.85%), *Amla Rasa* (14.28%), *Laghu Guna* (60.07%), *Ruksha Guna* (64.42%), *Tikshna Guna* (17.85%), *Snigdha Guna* (21.42%), *Guru Guna* (39.28%), *Sara Guna* (7.14%), *Mrudu Guna* (3.57%), *Ushna Virya* (42.85%), *Sheeta Virya* (57.14%), *Madhura Vipaka* (35.71%), *Katu Vipaka* (64.28%), *Kapha-Vatashamakata* (25%), *Kapha-Pittashamkata* (39.28%) and *Vata-Pittashamakata* (21.42%).

In *Nyagrodhadi Ghana Vati, Tikta-Katu-Kashaya Rasa, Laghu- Ruksha-Tikshna Guna, Ushna Virya* and *Katu Vipaka* might have corrected the *Kapha Dushti*. Along with this, it contains the *Tikta Rasa, Sheeta Virya* and *Madhura Vipaka*, which might have corrected the vitiation of *Pitta*. In this way, this preparation acted on *Kapha-Pitta* and also *Kaphavargiya Dushyas*. Thus, it provided significant relief in the disease *Madhumeha*. The alleviation of *Kapha* and *Pitta* also helped to remove the obstruction (*Avarana*) to the path of *Vata*, thereby alleviating its *Dushti*.

Probable mode of action of *Virechana* {#sec2-12}
--------------------------------------

As said by Acharya Sushruta, in the patients of *Madhumeha, Kapha* and *Pitta* are vitiated excessively and they remain lying in the lower part of the body. *Virechana* has the quality to eliminate both *Pitta* and *Kapha*. Also, it is the best *Shodhana* therapy for the elimination of *Dosha* lying in the lower parts of the body. By the elimination of *Kapha* and *Pitta*, obstructions are removed (*Avarana*), which are caused by the path of *Vata*. At the same time, the elimination of *Kapha* also alleviates the vitiated *Kapha Vargiya Dushyas*. In this way, the *Virechana* therapy reduced the vitiation of *Dosha* and the *Dushyas*. In this group, the *Shamana* therapy was given after the *Virechana*. When the *Shamana* drug was given to the patients whose vitiated Doshas were already eliminated by the *Virechana* therapy, it ultimately provided better relief in comparison with the *Shamana* therapy alone. The above-mentioned facts are evident from the results of this study, as the *Virechana* and Nyagrodhadi Ghanavati group (combined therapy) provided better relief in signs and symptoms of the patients of *Madhumeha*.

Conclusion {#sec1-5}
==========

*Avaranjanya Madhumeha* can be correlated with DM type 2 because Avarana-aggravated *Vata* causes depletion of Vital *Dhatu*, like *Oja, Majja* and *Vasa*, and affects the normal physiology. Sedentary life, lack of exercise, faulty food habits and improper medication precipitate the disease. Urbanization also plays a role in the enhancement of the disease. *Madhumeha* (type 2 DM) affects mostly individuals after the age of 40 years. Strong genetic predisposition is seen in Type 2 DM patients. Treatment modalities based on the consideration of vitiated *Kapha, Meda* and *Vata*, having properties like *Shleshamamedohara, Pramehaghna* and *Kapha-Vatahara*, should be used. In the present study, better relief was observed in signs and symptoms of the patients in comparison with the biochemical parameters. After evaluating the total effect of therapies, it was observed that the *Virechana* and *Nyagrodhadi Ghanavati* (combined therapy) provided better relief in the patients of *Madhumeha* in comparison with the *Nyagrodhadi Ghanavati* (*Shamana* therapy) alone.
